Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
Authors:
- Mick J.M. van EijsMEMick J.M. van Eijs
- M. Marlot van der WalMWM. Marlot van der Wal
- Noël M.M. DautzenbergNDNoël M.M. Dautzenberg
- Mark SchuivelingMSMark Schuiveling
- Rik J. VerheijdenRVRik J. Verheijden
- Fiona D.M. van SchaikFSFiona D.M. van Schaik
- Bas OldenburgBOBas Oldenburg
- Stefan NierkensSNStefan Nierkens
- the UNICIT ConsortiumTCthe UNICIT Consortium
- Karijn P.M. SuijkerbuijkKarijn P.M. Suijkerbuijk
- Femke van WijkFWFemke van Wijk
Preprint
Abstract
High-dose steroids constitute the cornerstone of first-line treatment for immune-related adverse events (irAEs) associated with immune checkpoint inhibitors, but compromise antitumor immunity. A deeper understanding of irAEs and their response to steroids can contribute to more targeted irAE management regimens. We took a multi-omics approach to identify blood- and tissue-based predictors of steroid response and to explore underlying mechanisms of steroid non-response in irAEs. In the blood, steroid non-response correlated with trends for elevated Tc1/Tc17 CD8 + T cells and serum interleukin (IL)-17, IL-6, IL-12 and IL-23 prior to initiation of steroids, along with persistent (CD8 + ) T cell proliferation and activation after start of steroids. A remarkably fast decrease in inflammatory gene signatures and lymphocyte infiltration was observed in colitis tissue of steroid responders obtained within 24h after initiation of steroids. Peripheral T cell PD-1 receptor occupancy was not associated with steroid response. Colitis tissue of steroid non-responders was enriched for activated CD4 + memory T cells and a pronounced type 1/17 immune response. Together, our findings suggest rapid immunological effects of steroids in circulating cells and irAE-affected tissue and support that an enhanced type 1/type 17 response is associated with steroid non-response in irAEs.Keywords
This publication has 61 references indexed in Scilit:
- Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibitionCancer Immunology, Immunotherapy, 2023
- Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced MelanomaJAMA Oncology, 2022
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic jointClinical & Translational Immunology, 2022
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityCancer Cell, 2022
- PeacoQC: Peak‐based selection of high quality cytometry dataCytometry Part A, 2021
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- Tumor necrosis factor–interleukin‐17 interplay induces S100A8, interleukin‐1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritisArthritis & Rheumatism, 2011
- Per‐channel basis normalization methods for flow cytometry dataCytometry Part A, 2009
- Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblastsJournal of Gastroenterology, 2007